CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Apr. 02, 2017	Apr. 03, 2016
Income Statement [Abstract]
Revenues	[1],[2]	$ 12,779	$ 13,005
Costs and expenses:
Cost of sales	[1],[3]	2,470	2,851
Selling, informational and administrative expenses	[1],[3]	3,308	3,385
Research and development expenses	[1],[3]	1,708	1,731
Amortization of intangible assets	[1]	1,186	1,006
Restructuring charges and certain acquisition-related costs	[1]	157	141
Other (income)/deductions––net	[1]	(1)	330
Income from continuing operations before provision for taxes on income	[1],[4]	3,951	3,561
Provision for taxes on income	[1],[5]	821	513
Income from continuing operations	[1],[5]	3,130	3,048
Discontinued operations––net of tax	[1]	0	0
Net income before allocation to noncontrolling interests	[1],[5],[6],[7]	3,130	3,048
Less: Net income attributable to noncontrolling interests	[1]	9	9
Net income attributable to Pfizer Inc.	[1],[5]	$ 3,121	$ 3,038
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[5]	$ 0.52	$ 0.49
Discontinued operations––net of tax (in dollars per share)	[1],[5]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[5]	0.52	0.49
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[5]	0.51	0.49
Discontinued operations––net of tax (in dollars per share)	[1],[5]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[5]	$ 0.51	$ 0.49
Weighted-average shares––basic	[1]	6,006	6,150
Weighted-average shares––diluted	[1],[8]	6,092	6,225
Cash dividends paid per common share (in dollars per share)	[1]	$ 0.32	$ 0.30

[1] Amounts may not add due to rounding.

[2] Medivation’s and Anacor’s commercial operations are included in our condensed consolidated statements of income, commencing from their respective acquisition dates of September 28, 2016 and June 24, 2016. Therefore, our results of operations for the first quarter of 2016 do not include financial results from Medivation or Anacor. On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The commercial operations of HIS are included in our condensed consolidated statements of income through February 2, 2017 and, therefore, our financial results for the first quarter of 2017 reflect approximately one month of legacy HIS domestic operations and approximately two months of legacy HIS international operations, while financial results in our condensed consolidated statements of income for the first quarter of 2016 reflect three months of legacy HIS global operations.

[3] Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

[4] Income from continuing operations before provision for taxes on income.

[5] Amounts for the three months ended April 3, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards.

[6] Amounts may not add due to rounding.

[7] Amounts may not add due to rounding.

[8] Amounts for the three months ended April 3, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see Notes to Consolidated Financial Statements––Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards included in our 2016 Financial Report).